Last reviewed · How we verify
TID Hydrocortisone
At a glance
| Generic name | TID Hydrocortisone |
|---|---|
| Also known as | Thrice-daily conventional immediate-release hydrocortisone |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Feasibility of Breathwork Intervention With Older Adults After Knee Surgery (NA)
- Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy (NA)
- Moringa Oleifera and Phoenix Dactylifera L. Effects on Cortisol and Breast Milk in Postpartum Depression (NA)
- Effect of a Transversus Abdominis Plane Block on Wound Healing, Stress, and Immune Response After a Cesarean Delivery (NA)
- Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) (PHASE1)
- Efficacy of Quantum Molecular Resonance Combined With Intense Pulsed Light in Mixed Dry Eye (NA)
- Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TID Hydrocortisone CI brief — competitive landscape report
- TID Hydrocortisone updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI